Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents

M. Iavicoli, D. Cucinotta, G. De Mattia, M. Lunetta, M. Morsiani, A. E. Pontiroli, G. Pozza

Research output: Contribution to journalArticlepeer-review

Abstract

The influence of combined therapy using insulin and oral hypoglycaemic agents on blood glucose control and on insulin secretion in Type 2 diabetic patients with secondary failure to oral hypoglycaemic agents was evaluated. Type 2 diabetic patients (n = 180) (98 normal-weight, 82 over-weight), at least 3 years from diagnosis, and having poor blood glucose control on oral hypoglycaemic agents for at least 3 months (fasting plasma glucose > 10.0 mmol l-1) despite intensive efforts at improvement, were included in the study. A single daily insulin injection (human ultralente), at a dose of 0.22 ± 0.07 U kg-1 d-1 in normal-weight and 0.33 ± 0.10 U kg-1 d-1 in over-weight patients, was added to the previous dietary and drug treatment for 6 months. A progressive and significant (2p <0.001) reduction of the mean daily blood glucose was observed during the first 3 months of combined therapy (from 13.2 ± 3.2 to 8.1 ± 2.1 mmol l-1 in normal-weight and from 13.4 ± 3.1 to 8.8 ± 2.3 mmol l-1 in over-weight patients), with no further significant changes thereafter. A significant increase (2p <0.001) in the mean daily C-peptide concentration (from 0.50 ± 0.30 to 0.71 ± 0.29 nmol l-1 in normal-weight and from 0.78 ± 0.36 to 1.00 ± 0.41 nmol l-1 in over-weight patients) took place during combined therapy. No changes of body weight (+1.5 ± 1.2 kg in normal-weight and + 1.0 ± 1.0 kg in over-weight patients) were observed.

Original languageEnglish
Pages (from-to)849-855
Number of pages7
JournalDiabetic Medicine
Volume5
Issue number9
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Fingerprint Dive into the research topics of 'Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents'. Together they form a unique fingerprint.

Cite this